<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006485</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068316</org_study_id>
    <secondary_id>MSKCC-00091</secondary_id>
    <secondary_id>NCI-2272</secondary_id>
    <nct_id>NCT00006485</nct_id>
  </id_info>
  <brief_title>Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open-Labeled, Non-Randomized Phase I Study Of Flavopiridol Administered With Irinotecan (CPT-11) In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining flavopiridol with irinotecan&#xD;
      in treating patients who have locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of flavopiridol when combined with irinotecan in&#xD;
           patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the clinical pharmacokinetics of this regimen, as well as the plasma levels of&#xD;
           the active metabolite SN-38 and metabolic product SN-38 glucuronide in these patients.&#xD;
&#xD;
        -  Determine, in a preliminary manner, the therapeutic activity of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the role of p21 relative to treatment response and apoptosis in these patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, open-label, non-randomized study of flavopiridol.&#xD;
&#xD;
      Patients receive irinotecan IV over 30 minutes followed 7 hours later by flavopiridol IV over&#xD;
      1 hour on days 1, 8, 15, and 22. Treatment continues every 6 weeks for a minimum of 2 courses&#xD;
      in the absence of disease progression or unacceptable toxicity. During the first week of the&#xD;
      second course, patients receive flavopiridol alone on day 1 and irinotecan alone on day 2.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of&#xD;
      6 patients in the initial cohort experience dose limiting toxicity during the first course of&#xD;
      treatment. An additional 10 patients are treated at the MTD.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44-50 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven locally advanced or metastatic solid tumor that is refractory to&#xD;
             standard therapy or for which no standard therapy exists&#xD;
&#xD;
          -  Eligible for treatment at the maximum tolerated dose only if disease accessible for&#xD;
             tissue biopsy by Tru-Cut, CT guidance, or endoscopy&#xD;
&#xD;
               -  Pleural effusions or abdominal ascites do not constitute adequate tissue for&#xD;
                  biopsy&#xD;
&#xD;
          -  No known CNS metastasis or primary CNS tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Total neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac arrhythmias, congestive heart failure, or myocardial infarction within the&#xD;
             past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing (during and for at least 2 months after study)&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 2 months&#xD;
             after study&#xD;
&#xD;
          -  No concurrent serious or uncontrolled infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior irinotecan allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No other concurrent investigational medication&#xD;
&#xD;
          -  No concurrent vitamins (except a single multivitamin tablet), antioxidants, or herbal&#xD;
             preparations or supplements&#xD;
&#xD;
          -  No concurrent subcutaneous heparin or heparinoids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary K. Schwartz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2003</verification_date>
  <study_first_submitted>November 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 13, 2009</last_update_submitted>
  <last_update_submitted_qc>December 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

